https://www.yiliao.com/index.php?action=history&feed=atom&title=CD279
CD279 - 版本历史
2026-04-18T01:39:45Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=CD279&diff=313653&oldid=prev
223.160.139.194：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-08T07:31:22Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[CD279]]</strong>，即<strong>[[程序性死亡受体1]]([[PD-1]])**，是表达在激活的**[[T细胞]]</strong>、[[B细胞]]及[[髓系细胞]]表面的一种重要受体，属于<strong>[[免疫球蛋白超家族]]</strong>。作为关键的<strong>[[免疫检查点]]</strong>蛋白，[[CD279]]与其配体[[CD274]]([[PD-L1]])或[[CD273]]([[PD-L2]])结合后，会通过抑制[[T细胞]]受体信号传导来降低免疫应答强度，从而维持机体免疫稳态。然而，肿瘤细胞常利用此机制实现<strong>[[免疫逃逸]]</strong>。目前，阻断[[CD279]]通路的抗体疗法已成为恶性肿瘤临床治疗的基石，显著改善了[[黑色素瘤]]、[[非小细胞肺癌]]及[[淋巴瘤]]等多种肿瘤的生存预后。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">CD279 (PD-1)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">程序性死亡受体1·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">CD279 Structure: Extracellular IgV domain binding to PD-L1</div><br />
</div><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">分类：[[I型跨膜蛋白]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">5133([[PDCD1]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">8760</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q15116</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约32-35kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">染色体定位</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2q37.3</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要配体</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[PD-L1]]/[[PD-L2]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">功能角色</th><br />
<td style="padding: 12px; color: #1e40af;">免疫抑制检查点</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">生物学机制：免疫系统调节的“负向开关”</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[CD279]]通过复杂的胞内信号级联反应发挥抑制作用，防止过度的免疫反应伤害正常组织：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>配体结合与磷酸化：</strong> 当[[CD279]]与[[PD-L1]]结合时，受体胞内段的<strong>[[ITIM]]</strong>和<strong>[[ITSM]]</strong>基序发生磷酸化。</li><br />
<li style="margin-bottom: 12px;"><strong>磷酸酶招募：</strong> 磷酸化的基序招募蛋白酪氨酸磷酸酶<strong>[[SHP-2]]</strong>，后者通过脱磷酸化作用抑制<strong>[[TCR]]</strong>（T细胞受体）下游的信号转导。</li><br />
<li style="margin-bottom: 12px;"><strong>代谢与增殖抑制：</strong> 阻断<strong>[[PI3K/AKT]]</strong>和<strong>[[RAS/MEK/ERK]]</strong>通路，导致[[T细胞]]活化受阻、细胞因子分泌减少，并诱导<strong>[[T细胞耗竭]]</strong>状态。</li><br />
</ul><br />
<br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床应用：针对 CD279 的抑制剂矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">药物名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">厂商(主要地位)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键客观缓解与获益指标</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[帕博利珠单抗]]([[K药]])</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[MSD]](默沙东)；全球广谱免疫龙头。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在[[NSCLC]]一线治疗中确立了 OS 获益标准。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[纳武利尤单抗]]([[O药]])</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[BMS]]；首个获批的 PD-1 抑制剂。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在[[黑色素瘤]]及[[肾细胞癌]]中展现长效获益。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[替雷利珠单抗]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[百济神州]]；Fc 段改良国产先行者。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在[[霍奇金淋巴瘤]]及[[胃癌]]中展现极高缓解率。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：从单一靶向向联合免疫管理演进</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
基于[[CD279]]的治疗方案正向个体化与精准化转型：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>标志物驱动筛选：</strong> 通过检测<strong>[[PD-L1表达]]</strong>、<strong>[[TMB]]</strong>及<strong>[[MSI-H/dMMR]]</strong>状态来预判响应可能性，实现精准给药。</li><br />
<li style="margin-bottom: 12px;"><strong>垂直与水平联合：</strong> 临床广泛采用 PD-1 抑制剂联合化疗、联合抗血管药物（如[[IO+TKI]]）或联合其他免疫检查点抑制剂（如[[LAG-3]]/[[CTLA-4]]）以克服单药耐药。</li><br />
<li style="margin-bottom: 12px;"><strong>irAE 规范化管理：</strong> 针对<strong>[[免疫相关不良事件]]</strong>（如免疫性肺炎、结肠炎），实施“早期监测、分级干预、激素主导”的标准化流程。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[CD274]]([[PD-L1]])：</strong> CD279 的主要配体，其表达水平是免疫治疗的核心评估指标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[免疫检查点阻断]]([[ICB]])：</strong> 通过药物阻断信号轴，重新激活 [[T细胞]] 的治疗策略。</li><br />
<li style="margin-bottom: 8px;"><strong>[[T细胞耗竭]]：</strong> [[CD279]] 长期高表达导致的功能衰竭状态。</li><br />
<li style="margin-bottom: 8px;"><strong>[[新抗原]]([[Neoantigens]])：</strong> 与 PD-1 抑制剂效力密切相关的高免疫原性蛋白。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Pardoll DM. (2012).</strong> <em>The blockade of immune checkpoints in cancer immunotherapy.</em> <strong>[[Nature Reviews Cancer]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该综述奠定了 PD-1 作为肿瘤免疫治疗核心靶点的理论基础。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Ribas A, Wolchok JD. (2018).</strong> <em>Cancer immunotherapy using checkpoint blockade.</em> <strong>[[Science]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：总结了 PD-1 抑制剂在实体瘤中的临床动力学特征及耐药进化模型。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
CD279 (PD-1) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联通路</td><br />
<td style="padding: 10px 15px; color: #334155;">[[PI3K/AKT]]•[[RAS/ERK]]•[[TCR信号]]•[[CD28共刺激]]•[[mTOR]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">协同靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CTLA-4]]•[[LAG-3]]•[[TIGIT]]•[[TIM-3]]•[[CD40]]•[[4-1BB]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[SinoCellGene协作]]•[[FDA]]•[[NMPA]]•[[AACR]]•[[ASCO]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[双抗/多抗研发]]•[[基因编辑敲除PD-1]]•[[耐药微环境重塑]]•[[新型免疫疫苗联合]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.139.194